Proactive Investors
17 Jul 2026, 09:09 UTC · 9w ago
Verdict
Headline takes no side. We score ATAI +0.90 across four claims — strongly bullish.
+0.90strongly bullish
More positive than 94% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Eli Lilly is acquiring AtaiBeckley for up to $3.8 billion, including $2.8 billion upfront and $1 billion in milestones.
More positive than 92% of claims this week
The deal centers on BPL-003, a psychedelic nasal spray for treatment-resistant depression currently in Phase III trials.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 85% of claims this week
The Trump administration has prioritized psychedelic-based treatments for depression and PTSD, creating a friendlier regulatory backdrop.
More positive than 77% of claims this week
RBC Capital Markets estimates the psychedelics industry could reach $12 billion in revenue by 2034.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 94% of ticker scores this week
Shares jumped over 30% following a takeover offer by Eli Lilly at a significant premium.
More positive than 63% of ticker scores this week
The company is expanding its portfolio into psychedelic medicine through a strategic acquisition with high revenue potential.
More positive than 57% of ticker scores this week
Mentioned as a successful example of the commercial model via its high sales of Spravato.
More positive than 52% of ticker scores this week
Mentioned as an active participant in the growth of the psychedelic market via a prior acquisition.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
More positive than 35% of relationship scores this week
[mutual] Both companies are competing in the market for psychedelic-derived treatments for depression.
More positive than 35% of relationship scores this week
[mutual] Both companies are competing in the psychiatric and psychedelic candidate market.
+2.8%
Price agrees with the score
$7.35 vs $7.15 close before publication (Jul 16) · not market-adjusted
ATAI chart →
